[go: up one dir, main page]

WO1996033282A3 - Transduction ex vivo a fort rendement de cellules a l'aide de preparations de retrovirus de recombinaison a titre eleve - Google Patents

Transduction ex vivo a fort rendement de cellules a l'aide de preparations de retrovirus de recombinaison a titre eleve Download PDF

Info

Publication number
WO1996033282A3
WO1996033282A3 PCT/US1996/005638 US9605638W WO9633282A3 WO 1996033282 A3 WO1996033282 A3 WO 1996033282A3 US 9605638 W US9605638 W US 9605638W WO 9633282 A3 WO9633282 A3 WO 9633282A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
recombinant retroviral
titer recombinant
vivo transduction
high titer
Prior art date
Application number
PCT/US1996/005638
Other languages
English (en)
Other versions
WO1996033282A2 (fr
Inventor
Douglas J Jolly
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to AU55682/96A priority Critical patent/AU5568296A/en
Priority to EP96913061A priority patent/EP0871756A2/fr
Priority to JP8531997A priority patent/JPH11503916A/ja
Publication of WO1996033282A2 publication Critical patent/WO1996033282A2/fr
Publication of WO1996033282A3 publication Critical patent/WO1996033282A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des compositions et méthodes permettant d'introduire ex vivo de l'acide nucléique dans des cellules T, dans des cellules non mitotiques et dans des cellules résistant aux techniques usuelles de transduction, par l'intermédiaire de préparations rétrovirales de recombinaison à titre élevé. Les produits de recombinaison du vecteur porté par les particules du rétrovirus de recombinaison codent pour la production d'un ou plusieurs produits géniques désirés d'un ou de plusieurs gènes d'intérêt correspondants dont l'un au moins a des applications thérapeutiques. Lors de leur réintroduction dans un patient, les cellules transduites produisent le produit génique souhaité en quantité suffisante pour traiter un état pathologique particulier.
PCT/US1996/005638 1995-04-20 1996-04-19 Transduction ex vivo a fort rendement de cellules a l'aide de preparations de retrovirus de recombinaison a titre eleve WO1996033282A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU55682/96A AU5568296A (en) 1995-04-20 1996-04-19 High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
EP96913061A EP0871756A2 (fr) 1995-04-20 1996-04-19 Transduction ex vivo a fort rendement de cellules a l'aide de preparations de retrovirus de recombinaison a titre eleve
JP8531997A JPH11503916A (ja) 1995-04-20 1996-04-19 高力価組換えレトロウイルス調製物による細胞の高効率エクスビボ形質導入

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42518095A 1995-04-20 1995-04-20
US08/425,180 1995-04-20

Publications (2)

Publication Number Publication Date
WO1996033282A2 WO1996033282A2 (fr) 1996-10-24
WO1996033282A3 true WO1996033282A3 (fr) 1996-12-12

Family

ID=23685512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005638 WO1996033282A2 (fr) 1995-04-20 1996-04-19 Transduction ex vivo a fort rendement de cellules a l'aide de preparations de retrovirus de recombinaison a titre eleve

Country Status (5)

Country Link
EP (1) EP0871756A2 (fr)
JP (1) JPH11503916A (fr)
AU (1) AU5568296A (fr)
CA (1) CA2216871A1 (fr)
WO (1) WO1996033282A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
AU8777898A (en) * 1997-08-11 1999-03-01 Chiron Corporation Methods for genetically modifying t cells
US5994134A (en) † 1998-05-04 1999-11-30 Canji, Inc. Viral production process
RU2478711C1 (ru) * 2011-12-19 2013-04-10 Открытое акционерное общество "Институт стволовых клеток человека" Способ повышения эффективности вирусной трансдукции

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022489A1 (fr) * 1993-04-06 1994-10-13 Targeted Genetics Corporation Genes hybrides destines a etre utilises dans la production de cellules t cytotoxiques independantes de cellules t auxiliaires
WO1994029438A1 (fr) * 1993-06-11 1994-12-22 Cell Genesys, Inc. Procede de production d'un virus a titre eleve et transduction a haut rendement de cellules mammiferes induite par retrovirus
WO1995007358A1 (fr) * 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Transfert efficace de genes dans des lymphocytes primaires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022489A1 (fr) * 1993-04-06 1994-10-13 Targeted Genetics Corporation Genes hybrides destines a etre utilises dans la production de cellules t cytotoxiques independantes de cellules t auxiliaires
WO1994029438A1 (fr) * 1993-06-11 1994-12-22 Cell Genesys, Inc. Procede de production d'un virus a titre eleve et transduction a haut rendement de cellules mammiferes induite par retrovirus
WO1995007358A1 (fr) * 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Transfert efficace de genes dans des lymphocytes primaires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G. FERRARI ET AL.: "An in vivo modl of somatic cell gene therapy for human severe combined immunodeficiency", SCIENCE, vol. 251, 1991, pages 1363 - 1366, XP000381747 *
M.C. LEAVITT ET AL.: "Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes", HUMAN GENE THERAPY, vol. 5, 1994, pages 1115 - 1120, XP002012405 *
R.C. HOEBEN ET AL.: "Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haemopoietic progenitor cells", THROMBOSIS AND HAEMOSTASIS, vol. 67, 1992, pages 341 - 345, XP002012407 *
V.J. DWARKI ET AL.: "Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 1023 - 1027, XP002012406 *

Also Published As

Publication number Publication date
AU5568296A (en) 1996-11-07
JPH11503916A (ja) 1999-04-06
EP0871756A2 (fr) 1998-10-21
CA2216871A1 (fr) 1996-10-24
WO1996033282A2 (fr) 1996-10-24

Similar Documents

Publication Publication Date Title
WO1995006743A3 (fr) Procedes et compositions de production a grande echelle de virus adeno-associe recombine
ZA968382B (en) Vector and method of use for nucleic acid delivery to non-dividing cells
ATE481490T1 (de) Strukturprotein von aav, seine herstellung und verwendung
AU4526193A (en) Binding competent oligomers containing 2', 5' linkages
CA2192215A1 (fr) Genome du virus adeno-associe recombine codant une proteine du virus de l'immunodeficience
IL173399A (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medical products for producing recombinant proteins in vivo
CA2184345A1 (fr) Expression genique coordonnee in vivo
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
WO2000031235A3 (fr) Sequences nucleotidiques et proteiques de gene nogo et procedes reposant sur ces sequences
Hogge et al. Gene transfer to primary normal and malignant human hemopoietic progenitors using recombinant retroviruses
Robinson Gene therapy—proceeding from laboratory to clinic
ATE271612T1 (de) Expressionskassette zur expression von beliebigen genen in pflanzensamen
BR9206049A (pt) Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica
WO1997026337B1 (fr) Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison
ATE274593T1 (de) Gewebe-oder zellspezifische herpessimplex virus replikation
WO1998011243A3 (fr) Virus a adn non mammalien qui possede une proteine de coque modifiee
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
EP0568537A4 (fr) Modification genetique de cellules endotheliales.
WO1998031800A3 (fr) Proteines humaines
CA2321964A1 (fr) Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine
HUP9900808A2 (hu) Eljárás nukleozid-5'-foszfát-észterek előállítására
CA2197286A1 (fr) Produits de synthdse d'acide nucleique pour l'expression de gdnes regulee par le cycle cellulaire, cellules contenant ces produits, et leur utilisation dans la preparation de medicaments
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
DE19639103A1 (de) Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
WO1996033282A3 (fr) Transduction ex vivo a fort rendement de cellules a l'aide de preparations de retrovirus de recombinaison a titre eleve

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2216871

Country of ref document: CA

Ref country code: CA

Ref document number: 2216871

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 531997

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996913061

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996913061

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996913061

Country of ref document: EP